earnings
confidence high
sentiment positive
materiality 0.75
Starling Oncology Q2 revenue up 34.6% to $161.3M; raises FY2026 guidance
Oncology Institute, Inc.
- Revenue $161.3M (+34.6% YoY); gross profit $27.2M (+55.2%).
- Net loss narrowed to $9.8M from $17.0M; EPS $(0.08) vs $(0.15).
- Adjusted EBITDA turned positive at $229K vs $(4.1M) loss in prior year.
- Specialty Pharmacy revenue up 58% YoY; added ~230,000 capitated lives in California.
- Raised full-year 2026 revenue and gross profit guidance.